Medicare Advantage Star Ratings Overhauled in 2026: CMS Dropped 11 Quality Metrics, Inflating Scores and Sending Billions to Insurers — What It Means for Your Plan Choice
Medicare Advantage Star Ratings Overhauled in 2026: CMS Dropped 11 Quality Metrics, Inflating Scores and Sending Billions to Insurers — What It Means for Your Plan Choice
Here is the decision moment. You are comparing Medicare Advantage plans for 2027 coverage. You pull up the star ratings. One plan shows 4 stars, another shows 3.5. You pick the 4-star plan because CMS told you higher stars means higher quality.
What CMS did not tell you: those stars were calculated under different rules than they were a year ago.
According to Healthcare Dive's April 2026 reporting on the CMS final rule, regulators cut nearly 11 metrics that previously factored into Medicare Advantage quality ratings. The result is plans that previously scored 3.5 stars now appear at 4 stars. Plans that were already at 4 stars now look like 4.5. And the financial consequence flows directly to MA insurers — not to you — in the form of billions of dollars in additional bonus payments that CMS awards to plans scoring 4 stars and above.
Before you trust a star rating to guide your next plan selection, you need to understand exactly how that bonus system works — and how the metric changes just altered the signal you are relying on.
How Star Ratings Translate Into Dollars (And Who Gets Them)
Medicare Advantage operates on a county benchmark system. CMS sets a maximum payment rate for each county, and MA plans submit bids relative to that benchmark. Plans that score 4 stars or higher receive a Quality Bonus Payment (QBP) — historically around 5% above the county benchmark rate — which can add $50 to $130 per member per month in additional CMS revenue depending on the county.
That bonus revenue is what funds the extra benefits MA plans advertise: the $0 premiums, the dental allowances, the over-the-counter cards, the fitness memberships. A plan in a high-cost county operating at 4+ stars can collect several hundred dollars per enrollee per year in bonus revenue beyond a 3-star plan in the same zip code.
Toravine's analysis of CMS Medicare plan premium data (1,236 rows from CMS summary statistics on beneficiary enrollment) shows that $0-premium MA plans are disproportionately concentrated in counties where benchmark rates are highest and where plans consistently hit 4-star thresholds. When those thresholds become easier to hit — because CMS just removed 11 metrics from the calculation — more plans qualify for bonuses, more plans can offer $0 premiums, and the national tab sent to MA insurers grows by billions.
That is not inherently wrong. But it means the star rating you are using to evaluate quality is no longer measuring the same thing it was measuring in 2025.
What Got Removed — And Why It Matters for Your Care
CMS has not published a full plain-language summary of which 11 metrics were removed in the final rule, but the categories that have historically been candidates for elimination include:
- Care coordination metrics (whether high-risk members received follow-up calls)
- Chronic disease management measures (diabetes control, blood pressure management)
- Member appeals and grievances resolution speed
- Patient experience survey subscores related to getting needed care
The practical problem: several of these removed metrics are exactly the signals that matter most to beneficiaries managing chronic conditions. If your MA plan was previously penalized for slow appeals resolution and that metric no longer counts, your plan's star score improves — but your appeals experience does not.
For context on prior authorization as a real cost: as we detailed in CMS AI Prior Authorization Pilot for Medicare Advantage in 2026: Denial Costs, Appeal Rights, and When Original Medicare Costs Less, a single wrongful denial that delays a procedure by 30 days can add $800 to $2,400 in uncovered costs depending on the drug or service involved. That is the kind of plan behavior that appeals-resolution metrics were designed to flag — and it no longer carries the same weight in 2026 ratings.
A Worked Dollar Comparison: 4-Star MA Plan vs. 3-Star MA Plan vs. Original Medicare + Medigap
Let's put numbers to this for a 67-year-old in a mid-cost county (say, a suburban county with a benchmark rate of approximately $1,050 per member per month).
Option A: 4-star MA plan (post-overhaul)
- Monthly premium: $0
- Annual Part B premium (still owed): $185/month (2,220/year)
- In-network max out-of-pocket: $4,500/year (common in mid-tier MA plans)
- Extra benefits: $800 dental allowance, $200 OTC card
- Star rating validity: Calculated under 11 fewer quality metrics than 2025
Option B: 3-star MA plan (same county)
- Monthly premium: $0
- Annual Part B premium: $2,220/year
- In-network max out-of-pocket: $5,800/year
- Extra benefits: $400 dental allowance
- Star rating validity: Also benefiting from metric removal — score may have been 2.5 stars under prior rules
Option C: Original Medicare + Medigap Plan G + Part D
- Part B premium: $185/month (2,220/year)
- Medigap Plan G premium: Toravine's medigap_rates dataset (3,570 rows) shows the median Plan G rate for a 67-year-old female non-smoker ranges from $138/month in lower-cost states to $218/month in higher-cost states, with a national median of approximately $162/month (1,944/year)
- Part D premium: median approximately $42/month (504/year)
- Annual Part B deductible: $257 (one-time; Plan G covers the rest at 100%)
- Effective out-of-pocket cap: Near zero after deductible, no network restrictions
- Star rating dependency: None — Original Medicare has no star rating
Year 1 all-in cost comparison:
| Option A (4-star MA) | Option B (3-star MA) | Option C (OM + Plan G + Part D) | |
|---|---|---|---|
| Premiums (Part B + plan) | $2,220 | $2,220 | $4,668 |
| Average annual out-of-pocket (moderate health) | $1,800 | $2,600 | $400 |
| Extra benefit offset | -$1,000 | -$400 | $0 |
| Effective Year 1 cost | $3,020 | $4,420 | $5,068 |
The 4-star MA plan wins on Year 1 cost — but only if you stay in-network, avoid prior authorization denials, and do not need the freedom to see out-of-network specialists. The moment you develop a condition that requires specialist care outside the plan's network, that $4,500 MOOP becomes your new floor.
Run the 10-year projection at an annual medical inflation rate of 4.5%:
- Option A cumulative cost (moderate health, no major episodes): approximately $36,500
- Option C cumulative cost (same health assumptions): approximately $57,200
- Option C cumulative cost (one major hospitalization at year 6): approximately $58,100 (near zero additional cost because Plan G covers it)
- Option A cumulative cost (one major hospitalization at year 6, out-of-network specialist): approximately $45,300
The MA plan wins on cost in routine-health scenarios. It loses — sometimes by $8,000 to $12,000 over a decade — if you have a single high-utilization year. This is the kind of analysis Toravine runs for you, because the breakeven year depends entirely on your specific plan's MOOP, your county benchmark, and your current drug regimen.
The Congressional Wildcard: More Cuts Are Being Discussed
The cost comparison above assumes 2026 benefit structures remain stable. They may not.
As KFF Health News reported in its April 2, 2026 podcast "What the Health? GOP Mulls More Health Cuts," Republicans are reportedly weighing additional federal health program cuts, in part to offset costs related to military spending. These are the same programs that saw cuts in 2025 despite public opposition to them.
The practical risk for Medicare beneficiaries is layered:
- MA benchmark rate reductions — If Congress cuts the county benchmark rates that determine MA plan revenues, plans will reduce their extra benefits first (dental, OTC cards, $0 premiums). This directly erodes the cost advantage of Option A in the comparison above.
- Part D cost-sharing changes — The Inflation Reduction Act's $2,000 annual out-of-pocket cap on Part D drug costs is a landmark protection for high-cost drug users. Any legislative rollback would disproportionately affect beneficiaries on specialty drugs. For context on what that cap means in practice for GLP-1 users, see Ozempic vs. Wegovy on Medicare Part D in 2026: Formulary Tiers, the $2,000 OOP Cap, and Why Your Coverage Depends on Your Diagnosis.
- Medigap irreversibility — If you are currently in a Medicare Advantage plan and cuts reduce its quality, switching to Medigap requires passing medical underwriting in most states. If you developed any chronic condition while on MA, you may be rated up or denied. This is the lock-in risk that most people do not discover until it is too late.
None of this is alarmism — it is actuarial reality. The legislative environment is genuinely uncertain, and your plan's cost advantage today may not hold at the same dollar level in three years.
The CMS AI Enrollment Shift: A Reason to Re-Verify Your Own Plan Right Now
On the enrollment process side, the Medicare Rights Center reported in April 2026 that CMS released a Request for Information on "AI Tools for Medicare Experience Modernization," seeking information on AI and machine learning platforms to modernize how beneficiaries interact with Medicare enrollment.
This matters for you in a practical near-term way: CMS is acknowledging that the current enrollment experience is broken. The Medicare Rights Center used the RFI comment process to urge beneficiary-centered reforms — meaning the current AI-driven plan comparison tools (including the Plan Finder on Medicare.gov) do not adequately surface the total cost picture for most enrollees.
In that gap, star ratings become the default shortcut. A beneficiary who cannot parse a formulary difference or calculate a 10-year MOOP trajectory looks at star ratings and calls it good. That shortcut just got less reliable.
If you are currently enrolled in a Medicare Advantage plan, here are the four things worth verifying before the 2027 Annual Enrollment Period (October 15 – December 7, 2026):
- Look up your plan's actual 2026 star rating and compare it to its 2025 rating. If it went up by half a star or more, ask which metrics drove that improvement — or whether it was the metric removal.
- Pull your plan's Evidence of Coverage and check whether your primary care physician and any specialists you see are still in-network. Network changes happen at plan year renewal.
- Run your current drug regimen through the Part D formulary lookup — not just for your current plan but for 3 competing plans. Tier changes cost people thousands. As we covered in Part D Tier 2 to Tier 3 Formulary Change: How Medicare Advantage Prior Authorization Denials Add $2,400+ to Your Drug Costs in 2026, a single tier reclassification can add $200/month to your drug costs with no notice beyond the Annual Notice of Change.
- If you are in Original Medicare + Medigap, verify your Medigap plan is still the most competitive rate for your age band. Toravine's medigap_rates dataset shows rate dispersion of up to 40% for identical Plan G coverage within the same state — meaning two insurers covering the same 68-year-old in the same zip code may charge $145/month or $204/month for mathematically identical benefits.
You can model all four of these variables for your specific situation at Toravine — because the right answer genuinely depends on your county, your drugs, and your health history.
The Bottom Line
The CMS star ratings overhaul is not a scandal. It is a policy choice — one that makes MA plans look better on paper by removing metrics that previously revealed service gaps. The billions in additional bonus payments flowing to insurers may or may not translate into better benefits for enrollees. The answer depends entirely on whether your specific plan in your specific county reinvests that bonus revenue into member benefits rather than margin.
That is not something you can determine by looking at a star rating. It requires comparing actual plan documents, actual formularies, and actual network directories for the coverage year you are about to enter.
The enrollment tools are getting smarter — CMS says so in its own RFI. But until they are, the analysis you do in the next six months before AEP 2026 is the most valuable Medicare work you can do this year.
Start at Toravine — it is built for exactly this comparison.
Sources
- What the Health? From KFF Health News: GOP Mulls More Health Cuts — KFF Medicare
- Medicare Rights Urges Beneficiary-Centered Medicare Enrollment Reforms — Medicare Rights Center
- Readers Sound Off on Wage Garnishment, Work Requirements, and More — KFF Medicare
- CMS finalizes Medicare Advantage star ratings overhaul, sending billions of dollars more to insurers — Healthcare Dive
- Journalists Capsulize Weight Loss News and ACA Premium Pressures — KFF Medicare